Nausea and vomiting of pregnancy. Excessive vomiting in pregnancy
Conditions
Interventions
Intervention 1: Intervention group: Balang paste one tablespoon (10 grams) half an hour before breakfast and dinner for a week. The maximum amount of use of balang paste was not found in Iranian medic
Sponsors
Kashan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: o Pregnant women aged 18-40 who have experienced mild to moderate NVP (based on PUQE-24). Therefore, people who need hospitalization in the first visit (severe NVP) are not included in the plan. The gestational age should be 16-6 weeks (based on the last menstrual period or ultrasound; of course, in cases where they did not have an ultrasound during the first visit, the gestational age will be confirmed with an ultrasound during the next visit). Absence of nausea and vomiting before pregnancy Not taking anti-nausea drugs 24 hours before the visit (such as ondansetron, metoclopramide, promethazine) Absence of allergy to citron (compound) Absence of severe pregnancy complications such as bleeding, risk of miscarriage No history of chronic diseases, alcoholism, smoking and drug addiction No history of diabetes before pregnancy Absence of gestational diabetes
Exclusion criteria
Exclusion criteria: Need for hospitalization during intervention (severe NVP) Taking anti-nausea drugs during the intervention (such as ondansetron, metoclopramide, promethazine) The presence of an allergy to citron (compound) during interventions Failure to refer for the second or third visit Non-cooperation in taking medication or placebo as prescribed. In case of forgetting to use it three times, the patient is excluded from the intervention (in case of forgetting or not using 3 to 5 doses in a row, the person should be excluded from the study) Nausea of ??pregnancy due to causes other than pregnancy (secondary) Occurrence of severe pregnancy complications such as bleeding, risk of miscarriage during intervention
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Various studies have reported the prevalence of nausea in 50 to 80% of pregnancies and the prevalence of vomiting and belching in 50% of cases (1). Its prevalence in Iran has not been widely evaluated, but in the study of Hamedan, the prevalence was 69.7% (37.4% of total cases were mild, 46.7% were moderate, and 16% were severe) (12) and in Kashan, the prevalence was reported to be 71.5% (26.5% of total cases). mild, 63.6% moderate and 9.8% severe) (13). Timepoint: Each patient is visited on four occasions (on arrival, on the third and seventh days of treatment, and on the sixth day after the end of treatment). Method of measurement: In each appointment, the PUQE and VAS questionnaires are completed, and in addition, in the first visit, the demographic information of the patients (including age, gestational age, number of pregnancies, number of births) and the drugs used are asked, and the self-limiting nature of the disease is explained. In the second to fourth visit, the remaining drugs are collected to check the compliance of the patients and the side effects of the interventions are recorded (in the side effects form). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatima Atouf
Kashan University of Medical Sciences
Outcome results
None listed